Stay updated on Pembrolizumab in Triple Negative Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Triple Negative Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Triple Negative Breast Cancer Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.7%
    Check dated 2025-06-20T06:41:58.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.2 to version 2.16.3.
    Difference
    0.1%
    Check dated 2025-06-13T00:55:08.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T20:52:58.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.
    Difference
    1.0%
    Check dated 2025-05-29T15:25:21.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-05-01T01:46:39.000Z thumbnail image
  7. Check
    76 days ago
    Change Detected
    Summary
    The webpage has undergone significant changes, including the removal of detailed information about a clinical trial for Pembrolizumab in treating metastatic triple negative breast cancer, while adding new identifiers and collaborators related to the study.
    Difference
    57%
    Check dated 2025-04-16T14:13:09.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Triple Negative Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Triple Negative Breast Cancer Clinical Trial page.